Wolf Anne M, Siadaty Mir, Yaeger Beverly, Conaway Mark R, Crowther Jayne Q, Nadler Jerry L, Bovbjerg Viktor E
Department of Public Health Sciences, 1710 Allied St, Suite 34, Charlottesville, VA 22903, USA.
J Am Diet Assoc. 2007 Aug;107(8):1365-73. doi: 10.1016/j.jada.2007.05.015.
To evaluate program and health care costs of a lifestyle intervention in a high-risk obese population.
Twelve-month randomized controlled trial comparing lifestyle case management to usual care.
SUBJECTS/SETTING: Health plan members (n=147) with obesity (body mass index >/=27) and type 2 diabetes.
Lifestyle case management entailed individual and group education, support, and referrals by registered dietitians. Those in the usual-care group received educational material.
Medical and pharmaceutical health care costs reimbursed by the participant's primary insurance company.
Total costs were modeled using the four-equation model using previous year cost as a predictor.
Net cost of the intervention was $328 per person per year. After incorporating program costs, mean health plan costs were $3,586 (95% confidence interval [CI]: -$8,036, -$25, P<0.05) lower in case management compared to usual care. The difference was driven by group differences in medical (-$3,316, 95% CI: -$7,829 to -$320, P<0.05) but not pharmaceutical costs (-$239, 95% CI: -$870 to $280, not statistically significant), with fewer inpatient admissions and costs among case management compared with usual care (admission prevalence: 2.8% vs 22.5% respectively, P<0.001).
Addition of a modest-cost, registered dietitian-led lifestyle case-management intervention to usual medical care did not increase health care costs and suggested modest cost savings among obese patients with type 2 diabetes. Larger trials are needed to determine whether these results can be replicated in a broader population. The findings can be judiciously applied to support that the addition of a registered dietitian-led lifestyle case-management program to medical care does not increase health care costs.
评估针对高危肥胖人群的生活方式干预项目及医疗保健成本。
为期12个月的随机对照试验,比较生活方式个案管理与常规护理。
研究对象/研究地点:健康计划成员(n = 147),患有肥胖症(体重指数≥27)及2型糖尿病。
生活方式个案管理包括由注册营养师提供的个人及团体教育、支持和转诊服务。常规护理组的成员则收到教育材料。
参与者的主要保险公司报销的医疗和药物保健成本。
使用四方程模型对总成本进行建模,以前一年的成本作为预测指标。
干预措施的净成本为每人每年328美元。纳入项目成本后,与常规护理相比,个案管理的平均健康计划成本低3586美元(95%置信区间[CI]:-8036美元,-25美元,P<0.05)。这种差异是由医疗费用的组间差异(-3316美元,95%CI:-7829美元至-320美元,P<0.05)驱动的,而不是药物成本(-239美元,95%CI:-870美元至280美元,无统计学意义),与常规护理相比,个案管理中的住院人数和费用较少(住院患病率分别为2.8%和22.5%,P<0.001)。
在常规医疗护理中增加一项成本适度、由注册营养师主导的生活方式个案管理干预措施,并未增加医疗保健成本,且表明在患有2型糖尿病的肥胖患者中可节省适度成本。需要进行更大规模的试验来确定这些结果是否能在更广泛的人群中得到重复。这些研究结果可明智地用于支持在医疗护理中增加由注册营养师主导的生活方式个案管理项目不会增加医疗保健成本这一观点。